Your browser doesn't support javascript.
loading
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft, Lorna; Wigmore, Eleanor M; Williamson, Stuart C; Ros, Susana; Eberlein, Cath; Moss, Jennifer I; Urosevic, Jelena; Carnevalli, Larissa S; Talbot, Sara; Bradshaw, Lauren; Blaker, Catherine; Gunda, Sreeharsha; Owenson, Venetia; Hoffmann, Scott; Sutton, Daniel; Jones, Stewart; Goodwin, Richard J A; Willis, Brandon S; Rooney, Claire; de Bruin, Elza C; Barry, Simon T.
Afiliación
  • Hopcroft L; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.
  • Wigmore EM; Early Data Science, Oncology Data Science, AstraZeneca, Cambridge, UK.
  • Williamson SC; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.
  • Ros S; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.
  • Eberlein C; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.
  • Moss JI; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.
  • Urosevic J; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.
  • Carnevalli LS; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.
  • Talbot S; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.
  • Bradshaw L; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.
  • Blaker C; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.
  • Gunda S; Information Technology, AstraZeneca, Chennai, Tamil Nadu, India.
  • Owenson V; Imaging Sciences, AstraZeneca, Cambridge, UK.
  • Hoffmann S; Imaging Sciences, AstraZeneca, Cambridge, UK.
  • Sutton D; Imaging Sciences, AstraZeneca, Cambridge, UK.
  • Jones S; Imaging Sciences, AstraZeneca, Cambridge, UK.
  • Goodwin RJA; Imaging Sciences, AstraZeneca, Cambridge, UK.
  • Willis BS; Bioscience Early Oncology, AstraZeneca, Boston, MA, USA.
  • Rooney C; Translational Medicine, AstraZeneca, Cambridge, UK.
  • de Bruin EC; Translational Medicine, AstraZeneca, Cambridge, UK.
  • Barry ST; Bioscience Early Oncology, AstraZeneca, Cambridge, UK. Simon.T.Barry@astrazeneca.com.
NPJ Breast Cancer ; 9(1): 76, 2023 Sep 19.
Article en En | MEDLINE | ID: mdl-37726304
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: NPJ Breast Cancer Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: NPJ Breast Cancer Año: 2023 Tipo del documento: Article